Side effects of high-dose intravenous immunoglobulins

Clinical Neuropharmacology

Volumn 20, Issue 5, 1997, Pages 385-393

  Stangel, Martin ^a   Hartung, Hans Peter ^b   Marx, Peter ^a   Gold, Ralf ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Immunotherapy; Intravenous immunoglobulins; IVIg; Side effects

Indexed keywords

ANALGESIC AGENT; IMMUNOGLOBULIN; PROPRANOLOL;

ASEPTIC MENINGITIS; BONE MARROW TOXICITY; CARDIOTOXICITY; DERMATOMYOSITIS; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; GUILLAIN BARRE SYNDROME; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MIGRAINE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

EID: 0030852514     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199710000-00002     Document Type: Review

References (88)

1. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA, Universitt Consortium Expert Panel. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995;273:1865-70.
2. Otten A, Vermeulen M, Bossuyt PMM. Intravenous immunoglobulin treatment in neurological diseases. J Neurol Neurosurg Psychiatru 1995;59:359-61.
3. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchance, intravenous immunoglobuin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-30.
4. van der Meche FGA, Schmitz PIM, the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-9.
5. Hahn AF, Bollon CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-77.
6. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann neurol 1994;36:838-45.
7. Azulay J-P, Blin O, Pouget J. et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study.Neurology 1994;44:429-32.
8. van den Berg LH, Kerkhoff H, Oey PL. et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-52.
9. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992;49:1233-6.
10. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-93.
11. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
12. Bain PG, Motomura M. Newsom-Davis J. et al Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-83.
13. Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 1992;42:1422-3.
14. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146:1365-8.
15. Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988;295:438-43.
16. Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin Exp Immnol 1994;(suppl 1)97:49-51.
17. Dalakas MC. Clinical benefits und immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 1996;(suppl 1)104:55-60.
18. Gross-Tsur V, Shalev RS, Kazir E, Engelbard D, Amir N. Intravenous high-dose gaammaglobulins for intractable childhood epilepsy. Acta Neurol Scand 1993;88:204-9.
19. van Engelen BGM, Renier WO, Weemaes CMR, Strengers PFW, Bernsen PJH, Notermans SLH. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome: an add-on study. Eur J Pediatr 1994;153:762-9.
20. Illum N, Taudorf K, Heilmann C, et al. Intravenous immunoglobulin: a single-blinded trial in children with Lennox-Gastaut syndrome. Neuropediatrics 1990;21:87-90.
21. Hart YM, Cortez M, Andermann F, et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994;44:1030-6.
22. Amato AA, Cornman EW, Kissel JT. Treatment of stiff-man syndrome with intravenous immunoglobulin. neurology 1994;44:1652-4.
23. Verma A, Bradley WG. High-dose intravenous immunoglobulin therapy in chronic progressive lumbosacral plexopathy. Neurology 1994;44:248-50.
24. Crisp D, Ashby P, Lune radiculoneuritis treated with intravenous immunoglobulin. Neurology 1996;46:1174-5.
25. Molina JA, Benito-León J, Bermejo F, Jiménez-Jiménez FJ, Oliván J. Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren's syndrome. J Neurol Neurosurg Psychiatry 1996;60:699.
26. Counsell CE, McLeod M, Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology 1994;44:1184-5.
27. Pless M, Ronthal M. Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 1996;46:583-4.
28. Helveston WR, Gilmore R. Treatment of Vogt-Koyanagi-Harada syndrome with intravenous immunoglobulin. Neurology 1996;46:584-5.
29. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994;(suppl 1)97:79-83.
30. NIH Consensus Conference. Intravenous immunoglobulin: prevention and treatment of disease. JAMA 1990;264:3189-93.
31. Bertorini TE, Nance AM, Homer LH, Greene W, Gelfand MS, Jaster JH. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 1996;19:388-91.
32. Brannagan TH, Nagle KJ, Lang DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-77.
33. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia N Engl J Med 1986;314:560-4.
34. Liblau R, Morel E, Bach J-F. Autoimmune diseases, IgA deficiency, and intravenous immunoglobulin treatment. Am J Med 1992;93:114.
35. McCluskey DR, Bout NAM. Anaphylaxis with intravenous gammaglobulin. Lancet 1990;336:874.
36. Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Arch Neurol 1993;50:135-6.
37. Lisak RP. Arthritis associated with circulating immune complexes following administration ol intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1996;135:85-88.
38. Koehler PJ, Koudstaal J. Lethal hypersensitivity myocarditis associated with the use of intravenous gammaglobulin for Guillain-Barré syndrome, in combination with phenytoin. J Neurol 1996;243:366-7.
39. Oomes PG, van der Meche FGA, Kleyweg RF, Dutch Guillain-Barré Study Group. Liver function disturbances in Guillain-Barré syndrome: a prospective longitudinal study in 100 patients. Neurology 1996;46:96-100.
40. Koffman B, Dalakas MC. Effect of high-dose intravenous immunoglobulin (IVIG) on hematological and serum chemistry profiles in the treatment of patients with neuromuscular diseases. Neurology 1995;(suppl 4)45:A235.
41. Lisak RP. Liver function in GBS. Neurology 1996;47:1606.
42. Oomes PG, van Doorn PA, van der Meché FGA. Liver function in GBS. Neurology 1996:1606.s
43. Ochs HD, Fischer SH, Virant FS, Lee ML, Kingdon HS, Wedgwood RJ. Non-A, non-B hepatitis and intravenous immunoglobulin Lancet 1985;1:404-5.
44. Williams PE, Yap PL, Gillon J, Crawford RJ, Urbaniak SJ, Galea G. Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin. Vox Sang 1989;57:15-8.
45. Björklander J, Cunningham-Rundles C, Lundin P, Olsson R, Sönderström R, Hanson LA. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 1988;84:107-11.
46. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T, Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
47. Echevarriá JM, León P, Domingo CJ, et al. Laboratory diagonosis and molecular epidemiology of an outbreak of hepatitis C virus infection among recipients of human intravenous immunoglobulin in Spain. Transfusion 1996;36:725-30.
48. Flora K, Schiele M, Benner K, et al. An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin. Ann Allergy Asthma Immunol 1996;76:160-2.
49. Lever AML, Webster ADB, Brown D, Thomas HC, Non-A, non-B hepatitis occuring in agammaglobulinaemic patienis alter intravenour immunoglobulin. Lancet 1984;ii:1062-64.
50. Jonas MM, Baton MJ, Bresee JS, Schneider LC. Clinical and virologic feature of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 1996;98:211-5.
51. Schiff RI. Transmission of viral infection through intravenous immune globulin. N Engl J Med 1994;331:1649-50.
52. Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996;(suppl 1)104:35-42.
53. Uemura Y, Uriya K, Hirao Y, et al. Inactivation and eliminationof viruses during the fracctionation of an intravenous immunoglobulin preparation: liquid heat treatment and polyethylene glycol fractionation. Vox Sang 1989;56:155-61.
54. Kempf C, Jentsch P, Barré-Sinoussi F, Morgenthaler JJ, Morell A, Germann D. Virus inactivation during production of intravenous immunoglobulin. Transfusion 1991;31:423-7.
55. Hénin Y, Maréchal V, Barré-Sinousssi F, Chermann J-C, Morgenthaler J-J. Inactivation and partition of human immunodeficiency virus during Kistler and Nistschmann fractionation of human blood plasma. Vox Sang 1988;54:78-83.
56. Ahsan N, Palmer BF, Wheeler D, Greenlee RG, Toto RD. Intravenous immunolglobulin-induced osmotic nephrosis. Arch Intern Med 1994;154:1985-7.
57. Rault R, Piraino B, Johnson JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36:83-6.
58. Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, Davies K. High-dose intravenous IgG treatment and renal function. Lancet 1991;337:457-8.
59. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-9.
60. Steward RRC, Winney RJ, Cash JD. Renal toxicity of intravenous immunoglobulin. Vox Sang 1993;65:244.
61. Ellie E, Combe C, Ferrer X. High-dose intravenous immunoglobulin and acute renal failure. N Engl J Med 1992;327:1032-3.
62. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 1996;28:451-3.
63. Verny M, Item C, Eymard B, Petitclerc T, Bouche P, Leger JM. A study of renal function in long-term treatment of peripheral nervous system diseases with intravenous immunoglobulin. Neurology 1996;46:A235.
64. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin N Engl J Med 1992;326:270-1.
65. Bower LR, Brey RL, Rogers SJ, Stroncek DF, Jackson CE. Intravenous immunoglobulin-induced neutropenia. Ann Neurol 1994;36:291.
66. Tam DA, Morton LD, Stroncek DF, Leshner RT. Neutropenia in a patient receiving intravenous immune globulin. J Neuroimmunol 1996;64:175-8.
67. Khouri IF, Ippoliti C, Gajewski J, Przepiorka D, Champlin RE. Neutropenias following allogenic bone marrow transplantion: response to therapy with high-dose intravenous immunoglobulin. Am J Hematol 1996;52:313-5.
68. Brox AG, Cournoyer D, Sternbach M, Spurl G. Hemolytic anemia following intravenous gammaglobulin administration. Am J Med 1987;82:633-5.
69. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM. Immune hemolysis, diseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992;120:926-8.
70. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion 1986;26:410-2.
71. Strobel E, Wüllenwwber J, Peters J. Nachweis und Nebenwirkungen von Isoantikorpern in intravenos applizierbaren Immunolobulinpräparaten. Infusionsther Transfusionsmed 1995;22:31-5.
72. Reinhard WH, Berchtold PK. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-4.
73. Dalakas MC. High-dose intravenous immunoglobulins and serum viscosity: risk of precipitating thrombembolic events. Neurology 1994;44:223-6.
74. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994;44:1180-1.
75. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-8.
76. Woodruff RK, Gigg AP, Firkin FC, Smith IL. Fetal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patinets. Lancet 1986;2:217-8.
77. Mobini N, Sarela A, Ahmed AR. Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann Allergy Asthma Immunol 1995;74:119-28.
78. Constantinescu CS, Chang AP, McCluskey LF. Recurrent migraine and intravenous immune globulin therapy. N Engl J Med 1993;329:584-4.
79. Sekul EA, Culper EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62.
80. Vera-Ramirez M, Charlet M, Parry GJ. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1992;42:1636-7.
81. Casteels-van Daele M, Wijndaele L, Hunninck K. Intravenous immune globulin and acute aseptic meningitis N Engl J Med 1990;323:614-5.
82. Watson JDG, Gibson J, Joshua DE, Kronenberg H. Aseptic meningitis associated with high dose intravenous immunoglobulin therapy. J Neurol Neurosurg Psychiatry 1991;54:275-6.
83. Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R. Reversible encephalopathy with vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin. Neurology 1996;46:250-1.
84. Harkness K, Howell SJL, Davies-Jones GAB. Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome. J Neurol Psychiatry 1996;60:586.
85. Chan-Lam D, Fitzsimons EJ, Douglas WS, Douglas WS. Alopecia after immunoglobulin infusion. Lancet 1987;i:1436.
86. Ayliffe W, Haeney M, Roberts SC, Lavin M. Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replaemenl therapy. Lancet 1992;339:558-9.
87. Donatini B, Goetz J, Hauptmann G. Uveitis and antineutrophil cytoplasmic antibody in immunoglobulin batches. Lancet 1992;339:1175-6.
88. Duhem C, Ries F, Dicato M. Intravenous immune globulin and hypothermia. Am J Hematol 1996;51:172-3.